A peer advisory forum for life science startup founders and C-level executives
- June 28, 2022
- 4PM PT
WHAT IS YOUR COMPANY WORTH?
The Art of Company Valuation
Program
You’ve started your life science company and are now working on a proof of concept and a plan for commercialization. Your innovation may drive the development of new drugs, diagnostics, or technology platforms to help patients. As you form partnerships to take your enterprise to the next level, the question will arise: What is your company worth?
discussion
This small group session will focus on understanding the value of a company’s underlying assets, even without launched products, revenue or preclinical milestones. The facilitators will review several approaches to asset validation in the life sciences, discuss some common mistakes in IP licensing that can impact a company’s worth, and look at best practices in data-driven approaches to setting valuations.
Founders Circle forums are reserved for founders and C-level executives of start-up life science companies. The event is co-hosted with Biolabs and there will be refreshments and networking following the discussion.
Please note that this forum is for founders and C-level executives. Space is limited to 40 participants. Participation in Founders Circle is limited and will be approved by LaunchBio.
Speakers
David Crean, PhD, Managing General Partner, Cardiff Advisory
David has +25 years buy- and sell-side expertise of M&A, partnering and investments within life sciences and healthcare working within strategic biopharma companies, private equity, investment banking and venture capital. He is the Managing General Partner of Equitos Venture Partners LLC, an emerging life sciences-focused investment fund. In parallel to Equitos, he is a limited partner for Suncoast Ventures and Mesa Verde Venture Partners, two life sciences venture funds focused on incubator through growth-stage companies. In parallel to his venture activities, he serves as Managing General Partner for Cardiff Advisory LLC, a boutique mergers & acquisitions investment banking and strategic advisory firm.
Jason Skolnik JD, Partner, Wilson Sonsini Goodrich & Rosati
Jason Skolnik is a corporate and securities partner in the San Diego office of Wilson Sonsini Goodrich & Rosati. His practice covers a broad range of general corporate and transactional matters, including mergers and acquisitions, venture capital financings, joint ventures, public offerings and disclosure matters, corporate finance, and corporate advisory work. Jason represents companies at all stages of their life cycle, from start-ups to public companies, in addition to venture capital and private equity firms. He represents companies in a wide variety of industries, including biotech, medical devices, and media and entertainment.
Scott Winder, MBA, Co-Head, Shareworks Valuation Service
Scott is responsible for managing the valuation practice and client engagements. Previously Scott was a Director with SVB Analytics, where he led the Life Science practice. Prior to SVB Analytics, Scott was at Deloitte in San Francisco, where he leveraged his experience in the biotechnology and biopharmaceutical industry segments with clients ranging from startups to multinational corporations. Scott has a master’s degree in business administration from the Haas School of Business (University of California at Berkeley) and a bachelor’s degree in human biology from Occidental College.